Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Reiser

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Cancer|August 1, 2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study GroupChristina Nickenig, Martin Dreyling, Eva Hoster, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2016
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryMartin Stangel, Ralf Gold, David Pittrow, et al.
European Journal of Haematology|May 4, 2017
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyMarcel Reiser, Michael Borte, Dörte Huscher, et al.
Case Reports in Oncology|September 5, 2017
Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate CancerAlexander C Bunck, Daniel Pinto Dos Santos, De-Hua Chang, et al.
Cancer Medicine|May 16, 2018
Rituximab maintenance therapy of follicular lymphoma in clinical practiceUlrich Dührsen, Stefanie Broszeit-Luft, Annette Dieing, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Clinical Chemistry and Laboratory Medicine|June 5, 2013
Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsTilman Steinmetz, Kathrin Kuhr, Uwe Totzke, et al.
Cancer Immunology, Immunotherapy : CII|October 24, 2012
Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I studyCarmen D Schweighofer, Armin Tuchscherer, Sabine Sperka, et al.
Journal of Cancer Research and Clinical Oncology|November 22, 2021
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia veraCarl C Crodel, Kathleen Jentsch-Ullrich, Marcel Reiser, et al.
Journal of the National Cancer Institute|May 2, 2007
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisHolger Schulz, Julia F Bohlius, Sven Trelle, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Cancer|August 1, 2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study GroupChristina Nickenig, Martin Dreyling, Eva Hoster, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2016
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryMartin Stangel, Ralf Gold, David Pittrow, et al.
European Journal of Haematology|May 4, 2017
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyMarcel Reiser, Michael Borte, Dörte Huscher, et al.
Case Reports in Oncology|September 5, 2017
Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate CancerAlexander C Bunck, Daniel Pinto Dos Santos, De-Hua Chang, et al.
Cancer Medicine|May 16, 2018
Rituximab maintenance therapy of follicular lymphoma in clinical practiceUlrich Dührsen, Stefanie Broszeit-Luft, Annette Dieing, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Clinical Chemistry and Laboratory Medicine|June 5, 2013
Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsTilman Steinmetz, Kathrin Kuhr, Uwe Totzke, et al.
Cancer Immunology, Immunotherapy : CII|October 24, 2012
Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I studyCarmen D Schweighofer, Armin Tuchscherer, Sabine Sperka, et al.
Journal of Cancer Research and Clinical Oncology|November 22, 2021
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia veraCarl C Crodel, Kathleen Jentsch-Ullrich, Marcel Reiser, et al.
Journal of the National Cancer Institute|May 2, 2007
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisHolger Schulz, Julia F Bohlius, Sven Trelle, et al.
Pageof 8